Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
- Innocan's therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it's LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions.
- Innocan's Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans.
- This is a key milestone for Innocan and marks our first step towards the FDA's recognition of our technology.
- We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible.